TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo-Controlled Phase 2a TrialRohit Loomba, George Kemble, Kathryn Jean Lucas et al.|Gastroenterology|2021Cited by 216
FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical modelsMarie O’Farrell, George Kemble|Scientific Reports|2022Cited by 96